share_log

Short Interest in Bioasis Technologies Inc. (OTCMKTS:BIOAF) Increases By 28.7%

Defense World ·  Feb 14, 2023 01:01

Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 32,300 shares, a growth of 28.7% from the January 15th total of 25,100 shares. Based on an average trading volume of 246,000 shares, the days-to-cover ratio is currently 0.1 days.

Bioasis Technologies Trading Down 20.5 %

Shares of OTCMKTS BIOAF opened at $0.02 on Tuesday. The stock has a market capitalization of $1.69 million, a PE ratio of -0.71 and a beta of 0.29. The stock's fifty day simple moving average is $0.05 and its two-hundred day simple moving average is $0.10. Bioasis Technologies has a 12-month low of $0.02 and a 12-month high of $0.23.

Get Bioasis Technologies alerts:

Bioasis Technologies Company Profile

(Get Rating)

biOasis Technologies, Inc operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier.

See Also

  • Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
  • Should Medtronic's Recent Colibri Patent Controversy Concern You?
  • Checkpoint Software Helps Cyber Security Stocks Bottom
  • Under Armour Stock, Gap and Crap, Here's Why
  • Is Chevron Positioned To Take Energy Sector Leadership?
  • What Does the Consumer Price Index Measure?

Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment